Cell Biochemistry and Biophysics

, Volume 62, Issue 3, pp 501–509 | Cite as

Unresolved Inflammation and Cancer: Loss of Natural Immune Surveillance as the Correct ‘Target’ for Therapy! Seeing the ‘Elephant’ in the Light of Logic

  • Mahin KhatamiEmail author

To begin this commentary, it is appropriate to remember the 1959 statement made by Peyton Rous (Nobel Laureate in Physiology or Medicine 1966) that “A hypothesis is best known by its fruits. What have been those of the somatic mutation hypothesis? It has resulted in no good thing as concerns the cancer problem, but in much that is bad… Most serious of all the results of the somatic mutation hypothesis has been its effect on research workers. It acts as a tranquilizer on those who believe in it.” This statement was made over 50 years ago and well before the genetic study of cancer was put on steroids!

As Americans observe the 40th anniversary of the institution of President Nixon’s war on cancer, a sobering fact is that, despite heavy public investment for more than four decades on cancer research, progress in understanding the biology of cancer and how to control it has been extremely slow and fragmentary like identifying an ‘Elephant’ in the dark. Few, if any of the data emanating...


Cancer Immune surveillance Yin and Yang Acute and chronic inflammation Oxidative stress Targeted therapy Tumoricidal Tumorigenic Neurodegenerative Autoimmune Immune-privileged Immune-responsive Aging 

Selected References by the Author

  1. 1.
    Khatami, M. (2011). Unresolved inflammation: ‘Immune tsunami’ or erosion of integrity in immune-privileged and immune-responsive tissues and acute and chronic inflammatory diseases or cancer. Expert Opinion on Biological Therapy, 11, 1419–1432.PubMedCrossRefGoogle Scholar
  2. 2.
    Khatami, M. (2009). Inflammation, aging and cancer: Tumoricidal vs tumorigenesis of immunity: A common denominator mapping chronic diseases. Cell Biochemistry and Biophysics, 55, 55–79.PubMedCrossRefGoogle Scholar
  3. 3.
    Khatami, M. (2008). “Yin and Yang” in inflammation: Duality in innate immune cell function and tumorigenesis. Expert Opinion on Biological Therapy, 8, 1461–1472.PubMedCrossRefGoogle Scholar
  4. 4.
    Khatami, M. (2011). Inflammation, aging and cancer: Friend or foe? In M. Khatami (Ed.), Inflammation, aging and cancer. Croatia: InTech Publishing (in press).Google Scholar
  5. 5.
    Khatami, M., Donnelly, J. J., Haldar, J. P., & Rockey, J. H. (1989). Massive follicular lymphoid hyperplasia in experimental chronic recurrent allergic conjunctivitis. Archives of Ophthalmology, 107, 433–438.PubMedCrossRefGoogle Scholar
  6. 6.
    Khatami, M. (2005). Developmental phases of inflammation-induced massive lymphoid hyperplasia and extensive changes in epithelium in an experimental model of allergy. Implications for a direct link between inflammation and carcinogenesis. American Journal of Therapeutics, 12, 117–128.PubMedCrossRefGoogle Scholar
  7. 7.
    Khatami, M. (2005). Cyclooxygenase inhibitor Ketorolac or mast cell stabilizers: Immunological challenges in cancer therapy. Letters to the Editor. Clinical Cancer Research, 11, 1350–1352.Google Scholar
  8. 8.
    Khatami, M. (2007). Standardizing cancer biomarkers criteria: Data elements as foundation of a database. M-CSF (Model Marker) for early detection of cancer. Cell Biochemistry and Biophysics, 47, 187–198.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Section on Immunology, Inflammation, Aging and Cancer, Cell Biochemistry and Biophysics (CBB)BethesdaUSA

Personalised recommendations